Grapefruit juice enhances the systolic blood pressure-lowering effects of dietary nitrate-containing beetroot juice

Article

Published Version

Creative Commons: Attribution-Noncommercial 4.0

Open Access

O'Gallagher, K. ORCID: https://orcid.org/0000-0003-2218-4763, Cardona, S. B., Hill, C., Al-Saedi, A., Shahed, F., Floyd, C. N. ORCID: https://orcid.org/0000-0001-9359-6381, McNeil, K., Mills, C. E. ORCID: https://orcid.org/0000-0002-8313-3700 and Webb, A. J. ORCID: https://orcid.org/0000-0002-8109-1877 (2020) Grapefruit juice enhances the systolic blood pressure-lowering effects of dietary nitrate-containing beetroot juice. British Journal of Clinical Pharmacology. ISSN 0306-5251 doi: https://doi.org/10.1111/bcp.14420 Available at http://centaur.reading.ac.uk/91195/

It is advisable to refer to the publisher's version if you intend to cite from the work. See Guidance on citing.

To link to this article DOI: http://dx.doi.org/10.1111/bcp.14420

Publisher: Wiley-Blackwell
All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the End User Agreement.

www.reading.ac.uk/centaur

CentAUR
Central Archive at the University of Reading
Reading’s research outputs online
ORIGINAL ARTICLE

Grapefruit juice enhances the systolic blood pressure-lowering effects of dietary nitrate-containing beetroot juice

Kevin O’Gallagher1,2 | Sarah Borg Cardona1 | Callum Hill1 | Ali Al-Saedi1 | Fawzia Shahed1 | Christopher N. Floyd1,2 | Karen McNeill1 | Charlotte E. Mills2,3,4 | Andrew J. Webb1,2

1School of Cardiovascular Medicine and Sciences, Department of Clinical Pharmacology, King’s College London British Heart Foundation Centre of Research Excellence, London, UK
2Biomedical Research Centre, Clinical Research Facility, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
3Department of Nutritional Sciences, School of Life Course Sciences, King’s College London, UK
4Current institution: Food and Nutritional Sciences, University of Reading, England, UK

Correspondence
Dr Andrew J. Webb, Senior Lecturer/Honorary Consultant in Cardiovascular Clinical Pharmacology, King’s College London British Heart Foundation Centre, Department of Clinical Pharmacology, 4 Floor North Wing, St Thomas’ Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. SE1 7EH. Email: andrew.1.webb@kcl.ac.uk

Aims: Dietary nitrate from sources such as beetroot juice lowers blood pressure (BP) via the nitrate–nitrite–nitric oxide (NO) pathway. However, NO and nitrite are inactivated via reoxidation to nitrate, potentially limiting their activity. Cytochrome P450-3A4 inhibition with troleandomycin prevents nitrite re-oxidation to nitrate in rodent liver. Grapefruit juice contains the CYP3A4 inhibitor furanocoumarin. We therefore hypothesized that grapefruit juice would enhance BP-lowering with beetroot juice by maintaining circulating [nitrite].

Methods: We performed a randomized, placebo-controlled, 7-hour crossover study in 11 healthy volunteers, attending on 3 occasions, receiving: a 70-mL shot of active beetroot juice (Beet-It) and either (i) 250 mL grapefruit juice (Active Beet+GFJ), or (ii) 250 mL water (Buxton, Active Beet+H2O); or (iii) Placebo Beet+GFJ.

Results: The addition of grapefruit juice to active beetroot juice lowered systolic BP (SBP): Active Beet+GFJ vs Active Beet+H2O (P=0.02), and pulse pressure, PP (P=0.0003). Peak mean differences in SBP and PP were seen at T = 5 hours: −3.3 mmHg (95% confidence interval [CI] −6.43 to −0.15) and at T = 2.5 hours: −4.2 mmHg (95% CI −0.3 to −8.2), respectively. Contrary to the hypothesis, plasma [nitrite] was lower with Active Beet+GFJ vs Active Beet+H2O (P=0.006), as was salivary nitrite production (P=0.002) and saliva volume (−0.34 mL/min [95% CI −0.05 to −0.68]). The taste score of Beet+GFJ was 1.4/10 points higher than Beet+H2O (P=0.03).

Conclusion: Grapefruit juice enhanced beetroot juice’s effect on lowering SBP and PP despite decreasing plasma [nitrite]. Besides suggesting more complex mechanisms, there is potential for maximising the clinical benefit of dietary nitrate and targeting isolated systolic hypertension.

KEYWORDS
blood pressure, cytochrome p450, nitric oxide
Dietary inorganic nitrate (NO\textsubscript{3}\textsuperscript{−}) is found in beetroot and green leafy vegetables. Beetroot juice has been shown to produce beneficial cardiovascular effects,\textsuperscript{4} decreasing blood pressure (BP) in both healthy volunteers\textsuperscript{5} and in patients with hypertension.\textsuperscript{3,5} Furthermore, independent of peripheral BP, in hypertensive patients with or at risk of diabetes mellitus, chronic treatment with beetroot juice over 6 months results in beneficial changes in cardiac chamber volume.\textsuperscript{5} Dietary nitrate also has additional benefits on platelets, endothelial function and mitochondrial efficiency.\textsuperscript{7,8}

Much of the recent focus on the nitrate-nitrite- nitric oxide (NO) pathway has been on the mechanisms of bioactivation: nitrate reduction to nitrite (i.e. via the enterosalivary circulation and lingual bacterial nitrate reductases\textsuperscript{9,10}), and nitrite reduction to NO (e.g. by deoxyhaemoglobin\textsuperscript{11}). However, the redox nature of these metabolic processes permits re-oxidation of NO back to nitrite and then nitrate. Indeed, before the enterosalivary pathway was characterised, nitrate and nitrite were thought to be merely biologically inert by-products of NO oxidation, rather than key components of an important NO synthase-independent mechanism of NO production.

The cytochrome P450 (CYP) enzymes, particularly CYP3A, present in gut enterocytes and the liver\textsuperscript{12} which play a major role in drug metabolism, may also be involved in nitrite oxidation. Using troleandomycin to inhibit CYP3A4, Curtis \textit{et al}. recently demonstrated inhibition of nitrite re-oxidation back to nitrate in rat liver homogenates.\textsuperscript{13} Grapefruit juice is recognised as interacting with many drugs via inhibition of CYP3A4,\textsuperscript{14} attributed to furanocoumarins.\textsuperscript{9,10} Thus, it is plausible that the co-ingestion of grapefruit juice with beetroot juice would decrease CYP3A4-mediated oxidation of nitrite to nitrate, resulting in an increased plasma nitrite concentration.

We hypothesised that grapefruit juice, when co-ingested with beetroot juice, would potentiate beetroot juice’s BP-lowering effect, via increased plasma nitrite concentration due to furanocoumarin-mediated CYP3A4 inhibition of nitrite oxidation.

2 | METHODS

2.1 | Approvals

Ethical approval for this study was obtained from the South East London Research Ethics Committee (REC; 10/H0802/52). Written informed consent was obtained from all volunteers prior to commencing any protocol-related procedures.

2.2 | Participants

Participants were healthy volunteers aged 18–45 years, with normal BP (systolic BP [SBP] 90–140 mmHg and diastolic BP [DBP] <90 mmHg), a body mass index (BMI) of 18–40 kg/m\textsuperscript{2} and without any recent illness or regular systemic medication (other than oral contraceptive pill).

What is already known about this subject

- Dietary nitrate (e.g. beetroot juice) lowers blood pressure via the nitrate–nitrite–nitric oxide pathway.
- Cytochrome P450-3A4 inhibition with troleandomycin prevents nitrite re-oxidation to nitrate in rodent liver.

What this study adds

- Grapefruit juice potentiated the systolic blood pressure-lowering effect of beetroot juice, despite decreasing plasma [nitrite] and salivary nitrite production.
- The haemodynamic mechanisms are unclear but may involve a synergistic dynamic effect and/or the production of nitric oxide species other than nitrite.

2.3 | Study design

A 3-visit randomised (for the 2 active beetroot juice visits), single-blind (with respect to active vs placebo beetroot juice), placebo-controlled crossover intervention design was used. The 3 different visits involved the consumption of either:

- Active beetroot juice (nitrate-containing; ~0.4 g) and golden grapefruit juice (Active Beet+GFJ) i.e. 70 mL of nitrate-containing beetroot juice shot (Beet-It James White Drinks, UK) with 250 mL of grapefruit juice (Golden Grapefruit Juice, Tropicana UK Ltd, UK).
- Active beetroot juice and water (Active Beet+H\textsubscript{2}O) i.e. 70 mL of nitrate-containing beetroot juice shot + 250 mL of low-nitrate water (<0.1 mg/L, Buxton Mineral Water, UK).
- Placebo beetroot juice (nitrate-depleted) and grapefruit juice (Placebo Beet+GFJ) i.e. 70 mL of nitrate-depleted beetroot juice shot (James White Drinks, UK) + 250 mL of grapefruit juice. The placebo beetroot juice is identical in appearance, taste, and smell to the active beetroot juice. This visit was performed once the volunteer had completed the 2 active beetroot juice visits.

Each of the visits lasted 7 hours. For the duration of the visit, participants sat in an examination chair with their feet resting on a stool (to avoid changes in posture affecting plasma [nitrite]).\textsuperscript{16} Blood pressure was measured in triplicate every 15 minutes from 1 hour (T = −1) before ingestion of the juice intervention at (T = 0) and until 6 hours postingestion. The BP for an individual at a given time point was taken as the average of the 3 (triplicate) readings. The BP readings from timepoints T = −1 to T = 0 were averaged to produce a
baseline reading. Blood pressure measurements were taken according to guidelines, using an automated BP monitor (Intellisense 705IT, Omron, UK). To avoid the action of BP recording interfering with the measurement of plasma [nitrate]/[nitrite], BP recordings were taken from the arm contralateral to that from which blood samples were taken. Recordings of heart rate were taken alongside BP recordings.

To ensure participants remained hydrated during the study visit, we adopted an optimised hydration protocol whereby at every hour following the juice intervention, participants consumed 250 mL of low-nitrate water (<0.1 mg/L, Buxton Mineral Water, UK). Participants were given 2 slices of toasted Hovis wholemeal thick brown bread just after T = 3 h.

Volunteers were asked to rate the taste of each intervention by giving it a score of between 1 and 10 (disgusting–delicious), immediately after drinking the intervention.

2.4 | Sample collection

Blood and saliva samples were taken immediately prior to ingestion of each of the juice interventions, then at 30-minute intervals for the first 3 hours, and hourly for the final 3 hours. At time points where BP and blood samples were taken, BP recordings were taken prior to blood sampling. Urine samples were collected every hour, and the pH and volume recorded. A urine dipstick was performed upon collection of the first urine sample to exclude the possibility of high nitrite concentrations due to the presence of a urinary tract infection.

At each blood draw, 6 mL of venous blood was drawn into a chilled syringe then transferred to a chilled green lithium heparin tube (Vacutainer, BD). Samples were immediately centrifuged at 4°C and 2000 g for 5 minutes (MIKRO 220R, Hettich, Germany), after which plasma was collected.

Prior to collection of saliva, volunteers were asked to avoid swallowing saliva for 2 minutes. They were then asked to drool all saliva into a collecting tube. The volume of saliva collected was recorded.

All plasma, saliva and urine samples were divided into 2 chilled 2-mL tubes and stored at −80°C.

2.5 | Sample analysis

Plasma and saliva samples were analysed for nitrate and nitrite concentrations using chemiluminescence, as described previously. The quantification of nitrate and nitrite in plasma and saliva was performed by an investigator who was blinded to the treatment allocation.

2.6 | Data analysis

In this pilot study, data was analysed using GraphPad Prism 8.0 (GraphPad Software Inc.). All data are expressed as mean ± standard error of the mean unless otherwise stated (e.g. non-parametric statistics [median ± interquartile range] for non-normally distributed data). Data were compared by 2-way ANOVA and/or 1-way ANOVA as appropriate, with Fisher’s LSD post-test. P < .05 was considered statistically significant.

3 | RESULTS

A total of 11 volunteers were enrolled in the study (of 11 potential volunteers screened, all 11 were eligible and randomised). Volunteer baseline demographics for the 11 participants are shown in Table 1. Of the 11 volunteers, 9 completed all 3 visits (the other 2 volunteers did not attend the Placebo Beet+GFJ visit). There were no adverse events attributed to study participation.

3.1 | Plasma

The addition of grapefruit juice to active beetroot juice (Active Beet+GFJ) had no effect on plasma [nitrate] compared to active beetroot juice with water (Active Beet+H2O); P = .38 (Figure 1A). Plasma nitrate was not measured for the Placebo Beet+GFJ intervention.

As anticipated, both Active Beet+GFJ and Active Beet+H2O significantly increased plasma [nitrite] compared to Placebo Beet+GFJ (both P < .0001). Comparison between the 2 active beet interventions found that the addition of grapefruit juice decreased mean plasma [nitrite] by ~14%; P = .006 (Figure 1B).

3.2 | Saliva

Grapefruit juice decreased nitrate secretion into the mouth (measured as total salivary nitrate and nitrite production), which was lower in Active Beet+GFJ than Active Beet+H2O (P = .02), with the peak difference occurring at T = 1.5 h: −437 μmol/h (95% confidence interval [CI] −844 to −30); see Figure 2A. Salivary nitrite production

| Parameter | Value |
|-----------|-------|
| Number of participants (n) | 11 |
| Sex (n male) | 8 |
| Age (y) | 23 ± 4 |
| Weight (kg) | 60.9 ± 9.8 |
| BMI (kg/m²) | 21.3 ± 1.9 |
| HR (beats/min) | 80 ± 14 |
| SBP (mmHg) | 122 ± 8 |
| DBP (mmHg) | 75 ± 8 |

Data are mean ± standard deviation
BMI, body mass index; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure

**TABLE 1** Clinical parameters of participants, taken at time of screening.
was markedly decreased by grapefruit juice: i.e. lower with Active Beet+GFJ than Active Beet+H2O ($P = .002$); see Figure 2B. Salivary [nitrate]:[nitrite] was higher with Active Beet+GFJ vs Active Beet+H2O ($P = .01$), with the peak difference occurring at $T = 0.5$ h: +7.4 (95% CI +1.5 to +13.3); see Figure 2C.

Dietary nitrate (Active Beet+H2O) increased salivary flow from baseline, $P = .02$ overall, and by 0.38 mL/min at 4 h (95% CI 0.16 to 0.61); see Figure 3A. Whilst grapefruit juice (Placebo Beet+GFJ) did not significantly decrease salivary flow relative to baseline, $P = .7$, grapefruit juice appeared to exert an astringent effect compared to Active Beet+H2O: salivary volume was decreased with Placebo Beet+GFJ ($P < .0001$) and Active Beet+GFJ ($P = .04$) with the peak difference occurring at $T = 4$ h: −0.34 mL/min (95% CI −0.05 to −0.68); see Figure 3A.

Grapefruit juice significantly increased the salivary pH when combined with dietary nitrate ($P = .005$) for Active Beet+GFJ vs Active Beet+H2O (Figure 3B). Dietary nitrate also increased salivary pH compared to grapefruit juice: Active Beet+H2O vs Placebo Beet+GFJ ($P < .0001$) with the peak difference occurring at $T = 3$ h: +0.37 (95% CI 0.16 to 0.58). Grapefruit juice without dietary nitrate resulted in decreased salivary pH: Placebo Beet+GFJ vs Active Beet+GFJ ($P < .0001$) with the peak difference occurring at $T = 3$ h: −0.53 (95% CI −0.26 to 0.80).

### 3.3 | Blood pressure

Baseline BP data are presented in Table 2.

The addition of grapefruit juice to active beetroot juice resulted in a lower SBP: Active Beet+GFJ vs Active Beet+H2O ($P = .02$), with the peak mean difference in SBP seen at $T = 5$ hours: −3.3 mmHg (95% CI −6.43 to −0.15); see Figure 4A. As expected, active nitrate-containing beetroot juice (Active Beet+GFJ) also lowered SBP vs Placebo Beet+GFJ ($P = .0005$). However, no difference in SBP was seen between Active Beet+H2O and Placebo Beet+GFJ. Relative to baseline, SBP was decreased by the active nitrate-containing beetroot juice combinations: Active Beet+GFJ ($P = .02$) and Active Beet+H2O ($P < .01$) but not by Placebo+GFJ ($P = .09$).

In contrast to SBP, grapefruit juice tended to increase DBP, i.e. Active Beet+GFJ vs Active Beet+H2O ($P = .04$); see Figure 4B. Moreover, Placebo Beet+GFJ resulted in a significant decrease in DBP vs Active Beet+GFJ ($P = .002$) but not Active Beet+H2O ($P = .1$). Relative to baseline, DBP was not decreased by any of the interventions (all $P = .2$).

Pulse pressure (PP) was decreased by Active Beet+GFJ vs Active Beet+H2O ($P = .0003$), with the peak mean difference in PP seen at $T = 2.5$ hours: −4.2 mmHg (95% CI −0.3 to −8.2); see Figure 4C.
Active Beet+GFJ decreased PP vs Placebo Beet+GFJ (C<.0001), with a peak mean difference in PP seen at T = 4 hours: −6.6 mmHg (95% CI −2.0 to −11.2). Similarly, Active Beet+H2O decreased PP vs Placebo Beet+GFJ (P=.006), with a peak mean difference in PP seen at T = 6 hours: −4.2 mmHg (95% CI −0.4 to −8.0).

Relative to baseline, PP was decreased by the active nitrate-containing beetroot juice combinations: Active Beet+GFJ (P=.04) and Active Beet+H2O (both P=.03).

Mean arterial pressure (MAP, calculated as DBP + 0.4 × PP) was not significantly changed by Active Beet+GFJ vs either Active Beet+H2O (P=.6) or vs Placebo Beet+GFJ (P=.7; data not shown). Relative to baseline, MAP was significantly decreased by Active Beet+GFJ (P=.04), but not by Active Beet+H2O (P=.1) or Placebo Beet+GFJ (P=.3; data not shown).

PP index (PPI, the ratio of the pulse pressure to MAP20) was significantly decreased by Active Beet+GFJ vs both Active Beet+H2O (P=.001) and Placebo Beet+GFJ (P=.0001). Active Beet+H2O decreased PPI vs Placebo Beet+GFJ (P=.01). Relative to baseline, PPI was decreased by Active Beet+GFJ (P=.03) and Active Beet+H2O (P=.01) and increased by Placebo Beet+GFJ (P=.01).

3.4 | Heart rate

The addition of grapefruit juice to Active beetroot juice resulted in a higher heart rate: Active Beet+GFJ vs Active Beet+H2O (P=.0009), but without any significant change at individual timepoints (Figure 5). Both Active Beet+GFJ and Active Beet+H2O increased heart rate compared to Placebo Beet+GFJ (P<.0001 and P=.0006).
respectively). Relative to baseline, heart rate was decreased by Active Beet+H2O (P = .03) and Placebo Beet+GFJ (P = .03), but not by Active Beet+GFJ (P = .09).

### 3.5 Urine

Grapefruit juice as Placebo Beet+GFJ increased urinary pH vs Active Beet+H2O (P < .0003) but not vs Active Beet+GFJ (P = .09; Figure 6).

### 3.6 Taste score

The addition of grapefruit juice to active beetroot juice resulted in a significantly higher taste score, suggesting a greater palatability compared to beetroot juice and water: Active Beet+GFJ vs Active Beet+H2O: +1.4 (95% CI 0.15 to 2.58), P = .03, and Placebo Beet+GFJ vs Active Beet+H2O: +1.56 (95% CI 0.16 to 2.95), P = .03. There was no significant difference in taste score between the 2 grapefruit juice-containing interventions (P = .7; Figure 7).

### 4 DISCUSSION

We have demonstrated that co-ingestion of grapefruit juice with dietary nitrate results in a potentiation of dietary nitrate’s effect in lowering SBP and PP, albeit without the hypothesised increase in plasma [nitrite]. Therefore, the effect on SBP was unlikely to have been via furanocoumarin-mediated CYP3A4 inhibition of nitrite oxidation. Indeed, plasma [nitrite] was lower with Active Beet+GFJ compared to the Active Beet+H2O (though DBP was slightly higher with Active Beet+GFJ vs Active Beet+H2O).

The potential mechanism(s) by which grapefruit juice (in the Beet+GFJ intervention) decreases plasma [nitrite] vs Beet+H2O will be considered by the kinetic processes (absorption, distribution, metabolism and secretion/excretion) at different anatomical sites.

In the oral cavity, grapefruit juice appears to have inhibited the metabolic conversion of nitrate to nitrite, as indicated by the increased salivary [nitrate]:[nitrite] ratio. This was associated with an unexpected increase in salivary pH with grapefruit juice. Whilst previous studies have suggested the relationship between salivary pH
FIGURE 4  The effect of grapefruit juice (GFJ) and beetroot juice (given at T = 0 h) on blood pressure (BP). (A) Systolic BP. (B) Diastolic BP. (C) Pulse pressure. n = 9 for all interventions and parameters assessed. Statistical significance shown as $^\dagger P < .05$, $^{\dagger\dagger} P < .01$, $^{\dagger\dagger\dagger} P < .001$, $^{\dagger\dagger\dagger\dagger} P < .0001$ as analysed by 2-way ANOVA between the curves and $^\# P < .05$, $^{\#\#} P < .01$ by 1-way ANOVA vs baseline.

FIGURE 5  The effect of grapefruit juice (GFJ) and beetroot juice (given at T = 0 h) on heart rate. n = 9 for all interventions and parameters assessed. Statistical significance shown as $^{\dagger\dagger\dagger} P < .001$, $^{\dagger\dagger\dagger\dagger} P < .0001$ as analysed by 2-way ANOVA between the curves and $^\# P < .05$ by 1-way ANOVA vs baseline.
and nitrate reduction is in the opposite direction, and these are models, or only checked at a single timepoint of 30 minutes, rather than full physiological/kinetic studies. Our finding requires confirmation in further detailed mechanistic studies.

A potential additional contributing factor is the lower total salivary volume with grapefruit juice. Whilst the astringent effect of grapefruit (juice) may account for the absolute decrease in the total salivary nitrate secretion (measured as the total amount of salivary nitrate and nitrite: a secretory/excretory kinetic mechanism), this would not account for the change in rate of conversion of nitrate to nitrite (a metabolic mechanism) as indicated by the relative salivary [nitrate]:[nitrite] ratio. It is therefore likely that both kinetic processes—decreased metabolism and secretion—contribute to the decreased absolute salivary nitrite production.

Grapefruit juice per se decreased salivary pH (Placebo Beet+GFJ) from baseline and compared to the other 2 interventions. Dietary nitrate tended to increase salivary pH, which has been reported previously and in combination with grapefruit juice resulted in a further increase in salivary pH. The mechanism for this interaction is not currently clear, although it could relate to carbonic anhydrase: quercetin, a flavonol found in grapefruit juice, has been demonstrated to inhibit human carbonic anhydrase in vitro. Grapefruit juice also acted to increase the urinary pH, further supporting an effect on carbonic anhydrase.

In the stomach, grapefruit juice might impact gastric pH, modifying the chemical reactions contributing to a lower plasma nitrite. Despite being a citrus fruit, ingestion of a similar volume of grapefruit juice as our study (180 mL) has been found to more than double gastric pH (from 1.39 ± 0.4 to 3.20 ± 0.3; P<.05), albeit in the presence of indinavir. Nitrite is reduced to NO and other NO species by acid disproportionation (with the remaining nitrite being absorbed into the systemic circulation) in the stomach: accordingly gastric NO production is inhibited by proton-pump inhibitors. In rats, increasing gastric pH with a proton-pump inhibitor diminished the BP-lowering effect of orally-ingested nitrite independently of plasma nitrite. Similar results with a dissociation between plasma nitrite and BP following proton-pump inhibitor administration have been found in the study by Montenegro and colleagues in humans. In their study, the plasma nitrite at 60 min following oral sodium nitrite ingestion, was significantly greater with the proton-pump inhibitor esomeprazole compared to placebo. However, the nitrite-induced BP decrease with placebo was blocked by esomeprazole. Therefore, the relationship between plasma nitrite and BP was comparable to our data. These data have important implications: stomach pH appears to be an important modulator of the enterosalivary pathway. However, dietary nitrate’s BP-lowering effect is not fully explained by an increase in plasma nitrite alone. Such uncoupling of the plasma nitrite from the clinical response suggests that other NO species may be involved which were not measured in this study e.g. thiocyanates in beetroot juice interacting to form S-nitrosothiols (increasing gastric pH with esomeprazole did not decrease S-nitrosothiol levels in the study of Montenegro et al). Altered gastric NO species may also have an effect on splanchnic blood flow, which may in turn impact systemic BP.
This study was designed to assess the effect of grapefruit juice, with the mechanism postulated to be mediated by furanocoumarins in the juice. However, grapefruit juice also contains a number of other substances that may play a role through mechanisms other than CYP3A4. For example, grapefruit juice is abundant in compounds which inhibit organic anion-transporting peptide and therefore potentially inhibits the uptake of organic anions; whether absorption of inorganic ions (such as nitrite) would be affected is not known. In addition to organic anion-transporting peptide, p-glycoprotein represents another possible mechanism by which grapefruit juice may affect gut absorption.

Grapefruit juice also contains reducing agents, such as ascorbic acid, which could reduce nitrite to NO in the gut, diminishing nitrite absorption into the plasma (however the preparation of beetroot juice used also contains 2% lemon juice, which itself will contain ascorbic acid). Other potential reducing agents found in grapefruit juice are flavonoids, naringin, kaempferol and quercetin. In the stomach, nitrite acid). Other potential reducing agents found in grapefruit juice are flavonoids, naringin, kaempferol and quercetin. In the stomach, nitrite and quercetin react to form NO, a process that is favoured by acidic conditions. Whilst, the short half-life of NO would suggest that NO produced in the stomach would have only direct local effects, this has the potential to indirectly affect systemic BP via splanchnic blood flow as suggested above. Currently there is no evidence of flavonols reducing nitrate systemically.

The enhanced SBP-lowering effects of dietary nitrate and grapefruit juice co-consumption could represent a synergistic dynamic effect. Placebo Beet+GFJ was associated with a trend to decrease SBP (P = .09). It is therefore possible that grapefruit juice has its own independent BP-lowering effect; however, this study was not designed to measure such an effect. Combining the BP-lowering effect of beetroot juice with grapefruit juice would therefore be expected to result in an enhanced BP-lowering effect compared to beetroot juice alone. Indeed, grapefruit juice contains several vasoactive compounds including naringin and quercetin. Naringin, when given daily for 6 weeks as grapefruit juice, has been shown to have a beneficial effect on arterial stiffness compared to treatment with a naringin-free grapefruit juice control and a single dose of quercetin has been shown to increase brachial artery diameter. Actions of these vasoactive compounds might therefore explain the decreased PP observed for Active Beet+GFJ vs Active Beet+H2O.

The results of this study have interesting potential clinical implications. The combination of beetroot juice with grapefruit juice decreased SBP and had a small but significant effect on increasing DBP. Therefore, the combination of the juices reduced PP (and PPI) but not MAP. Raised PP is highly prognostic for adverse cardiovascular events. Furthermore, given the adverse effect of a low DBP in patients with isolated systolic hypertension, an intervention which decreases SBP without affecting DBP has potential clinical utility.

5 | LIMITATIONS

This study had several limitations. This was a pilot study, involving a small number of participants, who were healthy volunteers. Larger studies of longer duration are required to confirm the findings reported in this paper and their applicability to patients with hypertension. In addition, in this study only the volunteers were blinded (to the Active vs Placebo Beet juice cocktails), therefore introducing the risk of bias. Future studies should be double-blinded to reduce this risk.

In this study BP was measured as peripheral BP. Given that inorganic nitrite is known to be an arterial dilator with selectivity for medium and large arteries over smaller resistance arterioles the effects on central BP may have been more marked than those on peripheral BP (as seen in the VaSera study, where 6 months treatments with beetroot juice was shown to decrease central, but not peripheral BP in hypertensive patients with/at risk of type 2 diabetes). It would therefore have been preferable to have recorded measures of central BP in addition to peripheral BP.

A further limitation of the study design is that both juices contain bioactive substances other than those being studied, including ascorbic acid and flavonoids in the grapefruit juice, and thiocyanates in the beetroot juice, therefore limiting the study's ability to describe mechanistic aspects of the enterosalivary circulation over and above the clinical end-point of BP decrease as a result of combining the 2 juices. Paradoxically, although the complex mix of bioactive juices is a limitation, so too is the simplicity of this study as it is unclear whether the clinical effects seen in this tightly controlled study are reproducible when added to a standard, mixed diet.

6 | CONCLUSION

In summary, our study found that grapefruit juice potentiated the SBP-lowering effect of beetroot juice, despite a decrease in plasma [nitrate]. Grapefruit juice appears to have inhibited the metabolic conversion of nitrate to nitrite, as indicated by the increased salivary [nitrate];[nitrite], associated with an increase in salivary pH with grapefruit juice. The BP-lowering effect may have been due to other NO species not measured in this study, such as S-nitrosothiols. These findings have implications for maximising the clinical benefit of dietary nitrate and also in further exploring mechanisms of dietary nitrate bioactivation. Given that the taste was improved by grapefruit juice, this combination has potential for use as a dietary approach to improve BP.

ACKNOWLEDGEMENTS

There was no support from any external organization specifically for the submitted work. We acknowledge internal infrastructure financial support from King's College London British Heart Foundation Centre; National Institute for Health Research (NIHR), Clinical Research Facility at Guy's & St Thomas' NHS Foundation Trust and NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
COMPETING INTERESTS
A.J.W. holds shares in HeartBeet Ltd, which receives a royalty from James White Drinks Ltd, which manufactures the beetroot juice used in this study. The other authors have no competing interests to declare.

CONTRIBUTORS
A.J.W. and C.E.M. conceived of and designed the study. A.J.W., K.O.G., S.B.C., C.H., A.A.-S., F.S. and K.M. performed data collection and data analysis. K.O.G., A.J.W. and C.F. were involved in data interpretation, drafting (and revision) of the manuscript. All authors have given final approval of this manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Kevin O’Gallagher https://orcid.org/0000-0003-2218-4763
Christopher N. Floyd https://orcid.org/0000-0001-9359-6381
Charlotte E. Mills https://orcid.org/0000-0002-8313-3700
Andrew J. Webb https://orcid.org/0000-0002-8109-1877

REFERENCES
1. Cicero AFG, Grassi D, Tocci G, Galletti F, Borghi C, Ferri C. Nutrients and nutraeuticals for the Management of High Normal Blood Pressure: an evidence-based consensus document. High Blood Press Cardiovasc Prev. 2019;26(1):9-25.
2. Webb AJ, Patel N, Loukogeorgakis S, et al. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension. 2008;51(3):784-790.
3. Kapil V, Kambata RS, Robertson A, Cauflield MJ, Alhuwalia A. Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study. Hypertension. 2015;65(2):320-327.
4. Ashor AW, Lara J, Servo M. Medium-term effects of dietary nitrate supplementation on systolic and diastolic blood pressure in adults: a systematic review and meta-analysis. J Hypertens. 2017;35(7):1353-1359.
5. Servo M, Lara J, Ogbonnwan I, Mathers JC. Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: a systematic review and meta-analysis. J Nutr. 2013;143(6):818-826.
6. Faconio L, Mills CE, Govoni V, et al. Cardiac effects of 6 months’ dietary nitrate and spirulonaclone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomised-controlled, VASERA TRIAL. Br J Clin Pharmacol. 2018;85(1):169-180.
7. Khatri J, Mills CE, Maskell P, Odongere C, Webb AJ. It is rocket science - why dietary nitrate is hard to ‘beet’! Part I: twists and turns in the realization of the nitrate-nitrite-NO pathway. Br J Clin Pharmacol. 2017;83(1):129-139.
8. Mills CE, Khatri J, Maskell P, Odongere C, Webb AJ. It is rocket science - why dietary nitrate is hard to ‘beet’! Part II: further mechanisms and therapeutic potential of the nitrate-nitrite-NO pathway. Br J Clin Pharmacol. 2017;83(1):140-151.
9. Doel JJ, Benjamin N, Hector MP, Rogers M, Allakar RP. Evaluation of bacterial nitrate reduction in the human oral cavity. Eur J Oral Sci. 2005;113:14-19.
10. Lundberg JO, Weitzberg E, Lundberg JM, Alving K. Intragastric nitric oxide production in humans: measurements in expelled air. Gut. 1994;35:1543-1546.
11. Cosky K, Partovi KS, Crawford JH, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med. 2003;9:1498-1505.
12. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of guccroxcoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest. 1987;80(4):1029-1036.
13. Curtis E, Hsu LL, Noguchi AC, Geary L, Shiva S. Oxygen regulates tissue nitrite metabolism. Antioxid Redox Signal. 2012;17(7):951-961.
14. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol. 1998;46(2):101-110.
15. Paine MF, Widmer WW, Hart HL, et al. A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr. 2006;83(5):1097-1105.
16. Liddle L, Monaghan C, Burleigh MC, Mclvenna LC, Muggeridge DJ, Easton C. Changes in body posture alter plasma nitrite but not nitrate concentration in humans. Nitric Oxide. 2018;72:59-65.
17. Mclvenna LC, Muggeridge DJ, Forrest Nee Whyte LJ, et al. Lower limb ischemic preconditioning combined with dietary nitrate supplementation does not influence time-trial performance in well-trained cyclists. J Sci Med Sport. 2019;22:852-857.
18. Nair A, Khan S, Omar S, et al. Remote ischaemic preconditioning suppresses endogenous plasma nitrite during ischaemia-reperfusion: a randomized controlled crossover pilot study. Br J Clin Pharmacol. 2017;83(7):1416-1423.
19. Ignarro LJ, Fukuto JM, Griscavage JM, Rogers NE, Byrns RE. Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: comparison with enzymatically formed nitric oxide from L-arginine. Proc Natl Acad Sci U S A. 1993;90(17):8103-8107.
20. Gray LJ, Spriigg N, Rashid PA, Willmot MR, Bath PM. Effect of nitrite ion donors on blood pressure and pulse pressure in acute and subacute stroke. J Stroke Cerebrovasc Dis. 2006;15(6):245-249.
21. Bojic DBA, Perovic J. The effects of dietary nitrate, pH and temperature on nitrate reduction in the human oral cavity. Physics. Chem Technol. 2004;3:53-60.
22. van Maanen JM, van Geel AA, Kleinjans JC. Modulation of nitrate-nitrite conversion in the oral cavity. Cancer Detect Prev. 1996;20(6):590-596.
23. Burleigh M, Liddle L, Muggeridge DJ, et al. Dietary nitrate supplementation alters the oral microbiome but does not improve the vascular responses to an acute nitrate dose. Nitric Oxide. 2019;89:54-63.
24. Innocenti A, Beyza Ozturk Sarikaya S, Gulcin I, Supuran CT. Carbonic anhydrase inhibitors inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010;18(6):2159-2164.
25. Shelton MJ, Wynn HE, Hewitt RG, DiFrancesco R. Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects. J Clin Pharmacol. 2001;41(4):435-442.
26. Pinheiro LC, Montenegro MF, Amaral JC, Ferreira GC, Oliveira AM, Tanus-Santos JE. Increase in gastric pH reduces hypotensive effect of orally ingested nitrite ischaemia-reperfusion: a randomized controlled crossover pilot study. Br J Clin Pharmacol. 2006;15(6):245-249.
27. Doel JJ, Benjamin N, Hector MP, Rogers M, Allakar RP. Evaluation of bacterial nitrate reduction in the human oral cavity. Eur J Oral Sci. 2005;113:14-19.
protease inhibitor saquinavir by grapefruit juice components. *Br J Clin Pharmacol.* 1999;48(4):543-552.

30. Takahama U, Oniki T, Hirota S. Oxidation of quercetin by salivary components. Quercetin-dependent reduction of salivary nitrite under acidic conditions producing nitric oxide. *J Agric Food Chem.* 2002; 50(15):4317-4322.

31. Rocha BS, Gago B, Barbosa RM, Laranjinha J. Dietary polyphenols generate nitric oxide from nitrite in the stomach and induce smooth muscle relaxation. *Toxicology.* 2009;265(1-2):41-48.

32. Giglio RV, Patti AM, Cicero AFG, et al. Polyphenols: potential use in the prevention and treatment of cardiovascular diseases. *Curr Pharm Des.* 2018;24(2):239-258.

33. Habauzit V, Verny MA, Milenkovic D, et al. Flavanones protect from arterial stiffness in postmenopausal women consuming grapefruit juice for 6 mo: a randomized, controlled, crossover trial. *Am J Clin Nutr.* 2015;102(1):66-74.

34. Perez A, Gonzalez-Manzano S, Jimenez R, et al. The flavonoid quercetin induces acute vasodilator effects in healthy volunteers: correlation with beta-glucuronidase activity. *Pharmacol Res.* 2014;89:11-18.

35. Selvaraj S, Steg PG, Elbez Y, et al. Pulse pressure and risk for cardiovascular events in patients with Atherothrombosis: from the REACH registry. *J Am Coll Cardiol.* 2016;67(4):392-403.

36. Franklin SS, Gokhale SS, Chow VH, et al. Does low diastolic blood pressure contribute to the risk of recurrent hypertensive cardiovascular disease events? *Framingham Heart Study Hypertens.* 2015;65:299-305.

37. Omar SA, Fok H, Tilgner KD, et al. Paradoxical normoxia-dependent selective actions of inorganic nitrite in human muscular conduit arteries and related selective actions on central blood pressures. *Circulation.* 2015;131(4):381-389, discussion 389

38. O’Gallagher K, Khan F, Omar SA, et al. Inorganic nitrite selectively dilates epicardial coronary arteries. *J Am Coll Cardiol.* 2018;71(3):363-364.

39. Mills CE, Govoni V, Facconti L, et al. Reducing arterial stiffness independently of blood pressure: the VaSera trial. *J Am Coll Cardiol.* 2017;70(13):1683-1684.

40. Mills CEGV, Facconti L, Casagrande L, et al. A randomised, factorial trial to reduce arterial stiffness independently of blood pressure: proof of concept? The ‘VaSera’ trial testing dietary nitrate and spironolactone. *Br J Clin Pharmacol.* 2019;86(5):891-902.

**How to cite this article:** O’Gallagher K, Borg Cardona S, Hill C, et al. Grapefruit juice enhances the systolic blood pressure-lowering effects of dietary nitrate-containing beetroot juice. *Br J Clin Pharmacol.* 2020;1–11. [https://doi.org/10.1111/bcp.14420](https://doi.org/10.1111/bcp.14420)